Dr. Reddy's acquires #Trademark rights of Breast cancer drug, #PRIMCYV, from #Pfizer Products India; #acquires rights for using it in the Indian market
#1QWithCNBCTV18 | #Pfizer reports #Q1 earnings.
▶️Net profit at ₹93.5 cr vs ₹32.5 cr (YoY)
▶️Revenue down 10.4% at ₹531.4 cr vs ₹592.9 cr (YoY)
▶️EBITDA down 42.3% at ₹110.8 cr vs ₹191.9 cr (YoY)
▶️Margin at 20.8% vs 32.4% (YoY) https://t.co/KYWVFh6gSS
▶️Net profit at ₹93.5 cr vs ₹32.5 cr (YoY)
▶️Revenue down 10.4% at ₹531.4 cr vs ₹592.9 cr (YoY)
▶️EBITDA down 42.3% at ₹110.8 cr vs ₹191.9 cr (YoY)
▶️Margin at 20.8% vs 32.4% (YoY) https://t.co/KYWVFh6gSS